相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gene Signatures for the Prediction of Response to Bacillus Calmette-Guerin Immunotherapy in Primary pT1 Bladder Cancers
Yong-June Kim et al.
CLINICAL CANCER RESEARCH (2010)
The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer
Paolo Gontero et al.
EUROPEAN UROLOGY (2010)
Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non-Muscle-Invasive Bladder Cancer
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2010)
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
Richard J. Sylvester et al.
EUROPEAN UROLOGY (2010)
Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group
Hirofumi Koga et al.
INTERNATIONAL JOURNAL OF UROLOGY (2010)
Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors
Ju-Seog Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association
Eiji Kikuchi et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Clinical outcome of high-grade non-muscle-invasive bladder cancer: A long-term single center experience
Shoichi Iida et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Jesus Fernandez-Gomez et al.
JOURNAL OF UROLOGY (2009)
Is Maintenance Bacillus Calmette-Guerin Really Necessary?
Harry W. Herr
EUROPEAN UROLOGY (2008)
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin:: Multivariate analysis of data from four randomized CUETO trials
Jesus Fernandez-Gomez et al.
EUROPEAN UROLOGY (2008)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
Marko Babjuk et al.
EUROPEAN UROLOGY (2008)
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events
J. Alfred Witjes et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
Harry W. Herr et al.
JOURNAL OF UROLOGY (2008)
Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy
Jared G. Heiner et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update
M. Craig Hall et al.
JOURNAL OF UROLOGY (2007)
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer:: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C
Antonio Ojea et al.
EUROPEAN UROLOGY (2007)
Age and outcome of superficial bladder cancer treated with bacille calmette-guerin therapy
Harry W. Herr
UROLOGY (2007)
The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study
Marc Colombel et al.
JOURNAL OF UROLOGY (2006)
Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Rui Fa Han et al.
UROLOGY (2006)
The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy
FN Joudi et al.
JOURNAL OF UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
RJ Sylvester et al.
UROLOGY (2005)
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?: Results of a prospective randomized trial
JA Martínez-Piñeiro et al.
JOURNAL OF UROLOGY (2005)
BCG dose reduction by decreasing the instillation frequency: Effects on local Th1/Th2 cytokine responses in a mouse model
EC de Boer et al.
EUROPEAN UROLOGY (2005)
Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2005)
Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer:: Formal meta-analysis of comparative studies on tumor progression
A Böhle et al.
UROLOGY (2004)
Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
MD Shelley et al.
BJU INTERNATIONAL (2004)
Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy
BP Schrier et al.
EUROPEAN UROLOGY (2004)
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2004)
Cytokine gene expression in a mouse model: The first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response
EC De Boer et al.
JOURNAL OF UROLOGY (2003)
Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
APM van der Meijden et al.
EUROPEAN UROLOGY (2003)
The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
RJ Sylvester et al.
EUROPEAN UROLOGY (2003)
Defining bacillus Calmette-Guerin refractory superficial bladder tumors
HW Herr et al.
JOURNAL OF UROLOGY (2003)
Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature
F Saint et al.
EUROPEAN UROLOGY (2003)
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity
A Bohle et al.
JOURNAL OF UROLOGY (2003)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer
JA Martínez-Piñeiro et al.
BJU INTERNATIONAL (2002)
A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
MD Shelley et al.
BJU INTERNATIONAL (2001)
Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials
M Huncharek et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
AR Zlotta et al.
EUROPEAN UROLOGY (2000)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
BCG intravesical instillations: Recommendations for side-effects management
P Rischmann et al.
EUROPEAN UROLOGY (2000)
分享论文
